Physician profile
Jeffrey A James
NPI 1316144868
$175,111.45
in general payments reported to CMS, 2019-2025
39 companies · $69K in 2025
The $69K reported for 2025 was more than what 98% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,398 · 2020: $3,464 · 2021: $1,890 · 2022: $16K · 2023: $36K · 2024: $46K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $57K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $34K · Food and Beverage: $9,114 · Travel and Lodging: $4,766 · Gift: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $57,049.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,400.00 |
| Consulting Fee | $34,140.00 |
| Food and Beverage | $9,113.94 |
| Travel and Lodging | $4,766.22 |
| Gift | $208.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $124,955.40 | 2019-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Conmed Corporation | $8,646.62 | 2023-2025 | Airseal, Helix, Abc Handpieces |
| Virtual Incision Corporation | $8,369.86 | 2024-2025 | Mira |
| Abbvie INC. | $7,395.06 | 2024-2025 | |
| Glaxosmithkline, LLC. | $7,190.58 | 2019-2025 | Jemperli, Zejula |
| Medical Device Business Services, INC. | $5,441.11 | 2023-2024 | Ethicon, Vistaseal, Surgiflo Hemostatic Matrix |
| Ethicon US, LLC | $4,079.91 | 2019-2025 | Surgicel Nu-Knit, Ethicon, Vistaseal |
| Pfizer INC. | $2,265.24 | 2023-2025 | |
| Tempus Ai, INC | $2,173.19 | 2024-2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals Lp | $1,404.34 | 2019-2025 | Lynparza |
| Genmab U.S., INC. | $897.09 | 2021-2025 | Tivdak |
| On Target Laboratories, INC | $750.00 | 2025 | Cytalux |
| Merck Sharp & Dohme LLC | $352.32 | 2020-2025 | Keytruda, Lynparza |
| Eisai INC. | $269.49 | 2021-2025 | |
| Clovis Oncology, INC. | $110.51 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $99.99 | 2022 | |
| Hologic Sales and Service, LLC | $83.29 | 2021-2024 | Thinprep 2000 Processor, Aptima |
| Myriad Genetic Laboratories, INC. | $71.15 | 2021-2024 | Myrisk |
| Davol INC. | $61.45 | 2023 | |
| C. R. Bard, INC. & Subsidiaries | $47.38 | 2024 | Bd Onclarity |
| Astellas Pharma US INC | $47.38 | 2023-2024 | Veozah |
| Tesaro, INC. | $37.77 | 2019 | |
| Pharmaand Gmbh | $36.72 | 2025 | Rubraca |
| Avanos Medical | $36.65 | 2023 | On-Q* Pump and Accessories |
| Immunogen, INC. | $36.61 | 2023 | Elahere |
| Teleflex LLC | $29.20 | 2022 | |
| Aroa Biosurgery Incorporated | $24.94 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $21.14 | 2025 | Sancuso |
| Boston Scientific Corporation | $20.39 | 2019 | |
| Smith+Nephew, INC. | $20.19 | 2024 | Pico |
| Integra Lifesciences Corporation | $20.14 | 2025 | Codman Hakim, Cusa Clarity, Codman Certas |
| Sumitomo Pharma America, INC. | $19.07 | 2024 | Myfembree |
| Daiichi Sankyo INC. | $17.93 | 2024 | Enhertu |
| Innovation Technologies INC | $16.41 | 2024 | Irrisept |
| Amag Pharmaceuticals, INC. | $14.65 | 2019 | |
| Meditrina | $13.42 | 2025 | |
| Amgen INC. | $12.20 | 2019 | |
| Dysis Medical, INC. | $11.62 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.